As the latest congressional stock trading disclosures trickle out, healthcare titans Johnson & Johnson (JNJ) and UnitedHealth Group (UNH) have emerged as fresh targets for Capitol Hill’s most closely watched portfolios. While several lawmakers have been trimming their positions, a cluster of members with seats on influential committees has been loading up on shares this year—igniting the perennial debate over whether mom-and-pop investors ought to simply copy their trades. The reality, however, is that the strategy carries hidden structural flaws that can leave retail portfolios dangerously exposed.
Federal filings show three House representatives have bought into Johnson & Johnson in 2026. Rep. Lloyd Doggett (D-Texas), who sits on the House Ways and Means Committee, the Budget Committee, and the Joint Committee on Taxation—with a reach spanning trade, oversight, and health policy—disclosed a purchase worth up to $15,000. Rep. Richard McCormick (R-Ga.) acquired a stake of the same size, while Rep. Lisa McClain (R-Mich.), whose subcommittee assignments include Health, went further with an investment of as much as $30,000. Far from a unified bullish signal, the filings also reveal notable selling pressure: Rep. Thomas Kean Jr. (R-N.J.) unloaded as much as $100,000 of JNJ, and Rep. Julie Johnson (D-Texas) shed up to $30,000, underscoring a clear split even among lawmakers with similar access to policy information.
On the UnitedHealth Group front, Sen. Markwayne Mullin (R-Okla.), a member of the Senate Committee on Health, Education, Labor, and Pensions, purchased between $50,001 and $100,000 worth of shares on February 25. In the House, Rep. Ro Khanna (D-Calif.) has been methodically building a position through a family trust, making three separate buys of up to $15,000 each since March 23. With JNJ up roughly 23% year to date and UNH surging more than 29% as of the relevant disclosures, the trades look at first glance like savvy wagers from politicians presumed to possess an information edge.
For retail investors tempted to mirror these moves, three critical pitfalls make copycatting a dangerous game.
The most lethal is the time lag. Under the STOCK Act, members of Congress have up to 45 days to publicly disclose their transactions. By the time a buy appears on a tracking website, the market has typically already priced in the news, earnings report, or policy shift that originally prompted the trade. Investors who act on that stale data effectively take positions long after the smart money has moved, often becoming reluctant bag-holders.
Second, a seemingly confident purchase may be nothing more than a routine portfolio adjustment. McClain’s $30,000 JNJ buy, for instance, could easily represent a rebalancing of a multimillion-dollar portfolio rather than a concentrated bet driven by non-public insight. Without knowing a lawmaker’s overall asset allocation, cost basis, or long-term financial objectives, isolating a single trade is akin to reading one sentence and claiming to understand the whole book.
Third, holding public office does not confer stock-picking genius. Lawmakers routinely buy near peaks and sell just before sharp rebounds. Moreover, healthcare behemoths like UnitedHealth are presently navigating antitrust scrutiny from the Department of Justice and billing investigations, creating regulatory overhangs that can trigger severe volatility. A diversified high-net-worth portfolio can absorb such shocks; an underdiversified retail account may not.
Instead of treating congressional disclosures as automatic buy signals, rational investors should use them as a launching pad for fundamental research. Both Johnson & Johnson and UnitedHealth Group boast compelling long-term track records, with dividend yields slightly above 2% and a decade-long history of steadily rising earnings per share and payouts. Yet the decision to commit capital must ultimately rest on an independent assessment of current valuations, balance-sheet strength, and personal risk tolerance. In the information food chain, retail investors are structurally disadvantaged. Abandoning the urge to blindly mimic politicians and returning to a discipline rooted in company fundamentals remains the far more reliable path to building wealth.
